MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Abeona Therapeutics Net Income 2011-2026 | ABEO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Abeona Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54.2 M | -39.7 M | -84.9 M | -84.2 M | -76.3 M | -56.7 M | -27.3 M | -21.9 M | -14.5 M | -26.8 M | 4.45 M | -10.5 M | -2.53 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.45 M | -84.9 M | -38.1 M |
Quarterly Net Income Abeona Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.16 M | 109 M | -12 M | - | -30.3 M | 7.41 M | -31.6 M | - | -11.8 M | -16.7 M | -9.11 M | - | -6.43 M | -4.1 M | -22 M | - | -7.04 M | -15.2 M | -16 M | - | -7.24 M | -13 M | -48.2 M | -16.4 M | -17.4 M | -23.9 M | -18.6 M | -17.5 M | -16.4 M | -12.2 M | -10.5 M | -8.45 M | -5.34 M | -8.28 M | -5.25 M | - | -2.62 M | -6.7 M | -5.54 M | - | -6.07 M | -4.11 M | -2 M | - | -1.47 M | -12.5 M | -859 K | - | -157 K | 1.6 M | 4.08 M | - | -14.9 M | -10.6 M | -4.89 M | - | 350 K | -1.26 M | -1.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | -48.2 M | -7.7 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-143 M | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Cabaletta Bio
CABA
|
-67.7 M | $ 3.34 | 0.45 % | $ 3.9 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
-65.3 M | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Cerus Corporation
CERS
|
-20.9 M | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 3.87 | -0.39 % | $ 116 M | France |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
CNS Pharmaceuticals
CNSP
|
-14.9 M | $ 3.23 | 2.22 % | $ 1.23 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
17 M | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
99.7 M | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amarin Corporation plc
AMRN
|
-59.1 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
214 M | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-44.6 M | $ 8.41 | -1.87 % | $ 36.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-45.9 M | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
-43.4 M | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
-46.3 M | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
|
Champions Oncology
CSBR
|
4.7 M | $ 6.14 | 3.89 % | $ 83.9 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-25.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-39.4 M | $ 0.72 | -2.34 % | $ 4.84 M | USA |
 |
Athira Pharma
ATHA
|
-96.9 M | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30.4 M | - | 17.91 % | $ 11.1 M | USA |
 |
Altimmune
ALT
|
-95.1 M | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
CEL-SCI Corporation
CVM
|
-27.6 M | $ 3.88 | -8.92 % | $ 247 M | USA |